COST-EFFECTIVENSS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS VS. ANGIOTENSIN II RECEPTOR BLOCKERS AS FIRST-LINE TREATMENT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

被引：0
|
作者：
Clark, L. A. [1 ]
Whitmire, S. M. [1 ]
Patton, S. [1 ]
Clark, C. A. [1 ]
Blanchette, C. M. [2 ]
机构：
[1] Univ North Carolina Charlotte, Charlotte, NC USA
[2] Univ N Carolina, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK14
引用
收藏
页码：A308 / A308
页数：1
相关论文
共 50 条
  • [41] Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?
    Ruschitzka, Frank
    Taddei, Stefano
    EUROPEAN HEART JOURNAL, 2012, 33 (16) : 1996 - 1998
  • [42] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues
    Mangrum, AJ
    Bakris, GL
    SEMINARS IN NEPHROLOGY, 2004, 24 (02) : 168 - 175
  • [43] Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease
    Gregg, L. Parker
    Richardson, Peter A.
    Herrera, Michael A.
    Akeroyd, Julia M.
    Jafry, Shehrezade A.
    Gobbel, Glenn T.
    Wydermyer, Sheena
    Arney, Jennifer
    Hung, Adriana
    Matheny, Michael E.
    Virani, Salim S.
    Navaneethan, Sankar D.
    AMERICAN JOURNAL OF NEPHROLOGY, 2023, 54 (3-4) : 126 - 135
  • [44] Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Early Period after Kidney Transplantation
    Orlic, Lidija
    Mikolasevic, Ivana
    Sladoje-Martinovic, Branka
    Bubic, Ivan
    Pavletic-Persic, Martina
    Racki, Sanjin
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 (03) : 809 - 814
  • [45] Comparative Effectiveness of Angiotensin Receptor II Blockers (ARBs) vs. Angiotensin-Converting Enzyme Inhibitors (ACEIs) in Hypertensive Elderly Patients with Cardiovascular Comorbidities
    Setoguchi, Soko
    Shrank, William H.
    Liu, Jun
    Mogun, Helen
    Winkelmayer, Wolfgang C.
    Dreyer, Nancy A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S234 - S234
  • [46] Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease
    Robert C. Stanton
    Current Diabetes Reports, 2013, 13 : 567 - 573
  • [47] Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease
    Stanton, Robert C.
    CURRENT DIABETES REPORTS, 2013, 13 (04) : 567 - 573
  • [48] Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases
    Agostini, Livia da Cunha
    Silva, Nayara Nascimento Toledo
    Belo, Vanessa de Almeida
    Luizon, Marcelo Rizzatti
    Lima, Angelica Alves
    da Silva, Glenda Nicioli
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 981
  • [49] Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers
    Sarzani, Riccardo
    Giulietti, Federico
    Di Pentima, Chiara
    Giordano, Piero
    Spannella, Francesco
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (16) : E10 - E13
  • [50] Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on prevention of stroke: Which one is better?
    Xiao, Lin
    Ouyang, Haichun
    Su, Qiwen
    Huang, Yuli
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 56 - 57
12345